FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a composition intended to prevent chemoresistance to antimitotic agents in breast cancer and lung adenocarcinoma cells and includes the antimitotic inhibitor SB743921 and the CDK8/19 inhibitor Senexin B.
EFFECT: obtaining a composition for preventing chemoresistance to antimitotic agents.
4 cl, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| NEUREGULIN ANTAGONISTS AND USE THEREOF IN TREATING MALIGNANT GROWTH | 2011 |
|
RU2587619C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| BACTERIALLY DERIVED, INTACT MINICELLS FOR DELIVERY OF THERAPEUTIC AGENTS TO BRAIN TUMOURS | 2012 |
|
RU2664698C2 |
| PHARMACEUTICAL FORMULATION FOR METASTASIS PREVENTION AND INCREASING OF TUMOUR SENSITISATION TO CHEMOTHERAPEUTIC AGENTS | 2007 |
|
RU2328282C1 |
| ONCOLYTIC ADENOVIRUS FOR TREATING CANCER, USING IT, AND PHARMACEUTICAL COMPOSITION CONTAINING IT | 2010 |
|
RU2536931C2 |
| METHOD AND COMPOSITION FOR TREATING CANCER | 2011 |
|
RU2541100C2 |
| ANTITUMOR COMPOSITION OF DOXORUBICIN WITH ATP INHIBITOR-DEPENDENT REVERSE CELL TRANSPORTER | 2018 |
|
RU2680834C1 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| METHOD OF SELECTING MEDICINAL PRODUCTS FOR PHARMACOLOGICAL INDUCTION OF MITOCHONDRIAL DYSFUNCTION IN MACROPHAGES FOR ANTITUMOR THERAPY | 2023 |
|
RU2810558C1 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
